Physician profile
Mark E Tanchel
NPI 1598762676
$6,135.62
in general payments reported to CMS, 2019-2025
40 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $267 · 2021: $554 · 2022: $1,044 · 2023: $1,081 · 2024: $1,251 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,254 · Education: $27.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,254.38 |
| Education | $27.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,153.47 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $879.50 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $676.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $633.07 | 2019-2024 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $632.11 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $360.88 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $231.35 | 2019-2025 | Rebyota, Clenpiq |
| Lilly USA, LLC | $201.97 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $126.46 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $115.56 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $112.72 | 2019-2025 | Ocaliva |
| Braintree Laboratories, INC. | $107.05 | 2019-2024 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $83.34 | 2023-2024 | Idacio |
| Merck Sharp & Dohme LLC | $82.15 | 2019-2022 | |
| Madrigal Pharmaceuticals | $67.73 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tanchel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.